NDAORALTABLET
Approved
Jul 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
P2Y12 Receptor Antagonists
Pharmacologic Class:
P2Y12 Platelet Inhibitor
Clinical Trials (5)
A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants
Started Aug 2024
28 enrolled
Healthy Participants
Ticagrelor De-escalation Strategy in AMI Patients
Started Mar 2023
2,312 enrolled
Acute Myocardial Infarction
Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world Registry
Started Mar 2023
6,789 enrolled
Acute Myocardial Infarction
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
Started Mar 2022
58 enrolled
Coronary Artery DiseaseHealthy Participants
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Started Aug 2021
140 enrolled
Hemorrhage, SurgicalBlood Loss, SurgicalBlood Loss, Postoperative+1 more
Loss of Exclusivity
LOE Date
Jul 27, 2036
126 months away
Patent Expiry
Jul 27, 2036
Patent Records (4)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8425934 | Apr 17, 2030 | Product | — |
| 8425934*PED | Oct 17, 2030 | — | |
| 10300065 | Jan 27, 2036 | U-2542 | |
| 10300065*PED | Jul 27, 2036 | — |